- Home
- DOMH vs FBIO Comparison
DOMH vs FBIO Comparison
Compare DOMH & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- FBIO
- Stock Information
- Founded
- DOMH 1967
- FBIO 2006
- Country
- DOMH United States
- FBIO United States
- Employees
- DOMH N/A
- FBIO N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- FBIO Health Care
- Exchange
- DOMH Nasdaq
- FBIO Nasdaq
- Market Cap
- DOMH 48.5M
- FBIO 44.0M
- IPO Year
- DOMH N/A
- FBIO N/A
- Fundamental
- Price
- DOMH $4.60
- FBIO $1.67
- Analyst Decision
- DOMH
- FBIO Strong Buy
- Analyst Count
- DOMH 0
- FBIO 3
- Target Price
- DOMH N/A
- FBIO $21.00
- AVG Volume (30 Days)
- DOMH 639.5K
- FBIO 210.8K
- Earning Date
- DOMH 04-15-2025
- FBIO 05-14-2025
- Dividend Yield
- DOMH 6.96%
- FBIO N/A
- EPS Growth
- DOMH N/A
- FBIO N/A
- EPS
- DOMH N/A
- FBIO N/A
- Revenue
- DOMH $18,146,000.00
- FBIO $57,675,000.00
- Revenue This Year
- DOMH N/A
- FBIO $63.20
- Revenue Next Year
- DOMH N/A
- FBIO $66.70
- P/E Ratio
- DOMH N/A
- FBIO N/A
- Revenue Growth
- DOMH 789.95
- FBIO N/A
- 52 Week Low
- DOMH $0.83
- FBIO $1.33
- 52 Week High
- DOMH $13.58
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- DOMH 52.92
- FBIO 54.70
- Support Level
- DOMH $3.70
- FBIO $1.45
- Resistance Level
- DOMH $4.78
- FBIO $1.64
- Average True Range (ATR)
- DOMH 0.42
- FBIO 0.11
- MACD
- DOMH 0.17
- FBIO 0.02
- Stochastic Oscillator
- DOMH 89.71
- FBIO 93.55
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.